Hualan Biological Vaccine Future Growth
Future criteria checks 5/6
Hualan Biological Vaccine is forecast to grow earnings and revenue by 33.3% and 28% per annum respectively. EPS is expected to grow by 33.2% per annum. Return on equity is forecast to be 14.6% in 3 years.
Key information
33.3%
Earnings growth rate
33.2%
EPS growth rate
| Biotechs earnings growth | 43.3% |
| Revenue growth rate | 28.0% |
| Future return on equity | 14.6% |
| Analyst coverage | Low |
| Last updated | 18 Sep 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 3,657 | 1,344 | N/A | 1,209 | 3 |
| 12/31/2025 | 3,116 | 1,114 | N/A | 1,061 | 4 |
| 12/31/2024 | 2,644 | 929 | N/A | 1,113 | 4 |
| 9/30/2024 | 1,650 | 498 | 695 | 750 | N/A |
| 6/30/2024 | 2,296 | 777 | 688 | 749 | N/A |
| 3/31/2024 | 2,300 | 805 | 724 | 792 | N/A |
| 12/31/2023 | 2,410 | 860 | 825 | 888 | N/A |
| 9/30/2023 | 1,984 | 645 | 752 | 813 | N/A |
| 6/30/2023 | 915 | 330 | 667 | 732 | N/A |
| 3/31/2023 | 1,956 | 614 | 459 | 533 | N/A |
| 1/1/2023 | 1,826 | 520 | 196 | 289 | N/A |
| 9/30/2022 | 1,997 | 598 | -162 | 233 | N/A |
| 6/30/2022 | 2,879 | 948 | -254 | 184 | N/A |
| 3/31/2022 | 1,833 | 624 | -216 | 274 | N/A |
| 1/1/2022 | 1,830 | 621 | -67 | 569 | N/A |
| 9/30/2021 | 2,608 | 1,004 | 124 | 608 | N/A |
| 6/30/2021 | 2,441 | 922 | 360 | 946 | N/A |
| 3/31/2021 | 2,439 | 934 | 285 | 897 | N/A |
| 12/31/2020 | 2,426 | 925 | 161 | 694 | N/A |
| 12/31/2019 | 1,049 | 375 | 131 | 275 | N/A |
| 12/31/2018 | 803 | 270 | 32 | 94 | N/A |
| 12/31/2017 | 285 | -77 | N/A | 22 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 301207's forecast earnings growth (33.3% per year) is above the savings rate (2.8%).
Earnings vs Market: 301207's earnings (33.3% per year) are forecast to grow faster than the CN market (26.3% per year).
High Growth Earnings: 301207's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 301207's revenue (28% per year) is forecast to grow faster than the CN market (13.9% per year).
High Growth Revenue: 301207's revenue (28% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 301207's Return on Equity is forecast to be low in 3 years time (14.6%).